{
  "id": 11413081,
  "title": "J&J reports two-year psoriasis drug data for high-impact sites",
  "url": "https://urgent.news/2026/10/02/j-j-reports-two-year-psoriasis-drug-data-for-high-impact-sites",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-02T10:08:37.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/jj-reports-twoyear-psoriasis-drug-data-for-highimpact-sites-93CH-4929357"
  },
  "original_language": "en",
  "account": null,
  "summary": "Johnson & Johnson (J&J) has released two-year data from its Phase 3 ICONIC-TOTAL study on the effectiveness of its oral medication, ICOTYDE (icotrokinra), in treating plaque psoriasis in high-impact areas such as the scalp, genitals, hands, and feet. The study, presented at the European Academy of Dermatology and Venereology Congress 2026, showed that 60% of patients with scalp psoriasis achieved complete skin clearance after 112 weeks, while 89% of patients with genital psoriasis and 63% with hand and foot psoriasis reached complete clearance. Overall skin clearance rates increased from 57% at Week 16 to 67% at Week 24 and 70% at Week 112. The company also noted improvements in nail psoriasis, with a mean percentage improvement in the modified Nail Psoriasis Severity Index rising from 33% at Week 16 to 62% at Week 52 and 71% at Week 112. The safety profile of ICOTYDE remained consistent, with no new safety signals identified. ICOTYDE is approved for treating moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years and older weighing at least 40 kg in the U.S., Europe, Japan, and China.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}